Table 1 Baseline characteristics of CPFE patients with LC and tumor features

Sex (male) [n (%)]

75 (93.8%)

Age (years)

68.1 ± 7.6

Smoking [n (%)]

66 (82.5%)

Pack-years

46.0 (25.0, 60.0)

Pathological type [n (%)]

 Adenocarcinoma

31 (38.8%)

 Squamous carcinoma

29 (36.3%)

 Adenosquamous carcinoma

2 (2.5%)

 Small cell carcinoma

13 (16.3%)

 Large cell carcinoma

1 (1.2%)

 NOS

4 (5%)

 T status 1/2/3/4 [n (%)]

24(30.0%)/25(31.3%)/9(11.2%)/22(27.5%)

 N status 0/1/2/3 [n (%)]

20(25.0%)/13(16.2%)/29(36.3%)/18(22.5%)

 M status 0/1 [n (%)]

42(52.5%)/38(47.5%)

 Staging I/II/III/IV [n (%)]

11(13.8%)/13(16.2%)/18(22.5%)/38(47.5%)

Localization [n (%)]

 Central lung cancer

22 (27.5%)

 Peripheral lung cancer

58 (72.5%)

Laboratory parameters

 WBC, *10⁹/L

7.2 (5.9, 8.0)

 ANC, *10⁹/L

4.4 (3.8, 5.4)

 ALC, *10⁹/L

1.6 (1.1, 2.1)

 NLR

2.8 (1.9, 4.3)

 CRP, mg/L

18.7 (5.2, 51.5)

 CEA, ng/mL

5.2 (2.2, 10.4)

 Fbg, g/L

3.9 (3.2, 4.8)

 D-dimer, mg/L

0.5 (0.2, 1.0)

 Surgical options [n (%)]

17 (21.3%)

 Wedge resection

2 (2.5%)

 Segmentectomy

1 (1.3%)

 Lobectomy

13 (16.2%)

 Pneumonectomy

1 (1.3%)